Home › Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program
 

Keywords :   


Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program

2014-07-30 10:52:33| drugdiscoveryonline Home Page

Humacyte, Inc., a pioneer in regenerative medicine, has announced that the U.S. Food and Drug Administration (FDA) has designated the HumaGraft development program for vascular access in hemodialysis patients as a Fast Track Development Program

Tags: program access fast track

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
05.11Tropical Storm Rafael Wind Speed Probabilities Number 6
05.11Tropical Storm Rafael Public Advisory Number 6
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 6
05.11Why colouring clothes has a big environmental impact
05.11Atlantic Tropical Weather Outlook
More »